As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...

Shares of Eli Lilly & Co. LLY sank 0.27% to $929.51 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.77% to 5,859.85 ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the ...